“We had viewed that BLA review as a relative gauge of what might happen with Stemline’s Elzonris in BPDCN. Overall, we remain bullish on Stemline and expect Elzonris to be approved ahead of its PDUFA (February 21). We reiterate our Buy rating and are raising our price target to $33. Lumoxiti which make us more bullish on Stemline ahead of the 1Q19 PDUFA. (a) Like Elzonris, Lumoxiti is not a classic ADC but a more compact toxin biologic (toxin conjugate of a variable anti-CD22 fragment). (b) Like BPDCN, HCL is a very rare heme tumor (under 1K patients/year). (c) Although the front-line therapy in HCL is generally a success by hem/onc standards (85% respond to front-line purine analogs), there is no standard of care for those who do not respond or those that eventually relapse (similar clinical picture and prognosis to BPDCN).”
According to TipRanks.com, Marango is a 4-star analyst with an average return of 16.1% and a 44.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Cyclacel Pharmaceuticals, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $35.50.
Based on Stemline Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.93 million. In comparison, last year the company had a GAAP net loss of $15.46 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.